187 related articles for article (PubMed ID: 32053702)
1. Treatment outcome of acute coronary syndrome patients admitted to Ayder Comprehensive Specialized Hospital, Mekelle, Ethiopia; A retrospective cross-sectional study.
Desta DM; Nedi T; Hailu A; Atey TM; Tsadik AG; Asgedom SW; Kasahun GG; Ayalew E
PLoS One; 2020; 15(2):e0228953. PubMed ID: 32053702
[TBL] [Abstract][Full Text] [Related]
2. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
[TBL] [Abstract][Full Text] [Related]
3. Optimizing prevention and guideline-concordant care in Montenegro.
Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M
Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861
[TBL] [Abstract][Full Text] [Related]
4. Acute coronary syndromes: clinical characteristics, management, and outcomes at the American University of Beirut Medical Center, 2002-2005.
Abdallah M; Karrowni W; Shamseddeen W; Itani S; Kobeissi L; Ghazzal Z; Alam S; Dakik HA
Clin Cardiol; 2010 Jan; 33(1):E6-E13. PubMed ID: 20014175
[TBL] [Abstract][Full Text] [Related]
5. [SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS].
Yahia DH; Pereg D; Lishner M; Elis A
Harefuah; 2015 May; 154(5):299-302, 339-40. PubMed ID: 26168639
[TBL] [Abstract][Full Text] [Related]
6. Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland.
Welker J; Auer R; Gencer B; Muller O; Cornuz J; Matter CM; Mach F; Windecker S; Rodondi N; Nanchen D
Swiss Med Wkly; 2016; 146():w14275. PubMed ID: 26859223
[TBL] [Abstract][Full Text] [Related]
7. Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction.
Raposeiras-Roubín S; Abu-Assi E; Cespón-Fernández M; Ibáñez B; García-Ruiz JM; D'Ascenzo F; Simao Henriques JP; Saucedo J; Caneiro-Queija B; Cobas-Paz R; Muñoz-Pousa I; Wilton SB; González Juanatey JR; Kikkert WJ; Núñez-Gil I; Ariza-Solé A; Song X; Alexopoulos D; Liebetrau C; Kawaji T; Gaita F; Huczek Z; Nie SP; Yan Y; Fujii T; Correia L; Kawashiri MA; Kedev S; Southern D; Alfonso E; Terol B; Garay A; Zhang D; Chen Y; Xanthopoulou I; Osman N; Möllmann H; Shiomi H; Giordana F; Kowara M; Filipiak K; Wang X; Fan JY; Ikari Y; Nakahayshi T; Sakata K; Yamagishi M; Kalpak O; Íñiguez-Romo A
Rev Esp Cardiol (Engl Ed); 2020 Feb; 73(2):114-122. PubMed ID: 31105064
[TBL] [Abstract][Full Text] [Related]
8. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
Lee HY; Cooke CE; Robertson TA
J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
[TBL] [Abstract][Full Text] [Related]
9. Prescription Rates of Guideline-Directed Medications Are Associated With In-Hospital Mortality Among Japanese Patients With Acute Myocardial Infarction: A Report From JROAD - DPC Study.
Nakao K; Yasuda S; Nishimura K; Noguchi T; Nakai M; Miyamoto Y; Sumita Y; Shishido T; Anzai T; Ito H; Tsutsui H; Saito Y; Komuro I; Ogawa H
J Am Heart Assoc; 2019 Apr; 8(7):e009692. PubMed ID: 30909774
[TBL] [Abstract][Full Text] [Related]
10. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
Mathews R; Wang TY; Honeycutt E; Henry TD; Zettler M; Chang M; Fonarow GC; Peterson ED;
Am Heart J; 2015 Jul; 170(1):62-9. PubMed ID: 26093865
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study.
Bruggmann C; Iglesias JF; Gex-Fabry M; Fesselet R; Vogt P; Sadeghipour F; Voirol P
Am J Cardiovasc Drugs; 2020 Feb; 20(1):105-115. PubMed ID: 31300969
[TBL] [Abstract][Full Text] [Related]
12. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
Makam RC; Erskine N; McManus DD; Lessard D; Gore JM; Yarzebski J; Goldberg RJ
Am J Cardiol; 2016 Dec; 118(12):1792-1797. PubMed ID: 27743577
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the Improving Care for Cardiovascular Disease in China (CCC) project: A national effort to prompt quality enhancement for acute coronary syndrome.
Hao Y; Liu J; Liu J; Smith SC; Huo Y; Fonarow GC; Ma C; Ge J; Taubert KA; Morgan L; Guo Y; Zhang Q; Wang W; Zhao D;
Am Heart J; 2016 Sep; 179():107-15. PubMed ID: 27595685
[TBL] [Abstract][Full Text] [Related]
14. Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events.
Awad HH; Zubaid M; Alsheikh-Ali AA; Al Suwaidi J; Anderson FA; Gore JM; Goldberg RJ
Am J Cardiol; 2011 Nov; 108(9):1252-8. PubMed ID: 21880292
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
[TBL] [Abstract][Full Text] [Related]
16. Management, clinical outcomes, and its predictors among heart failure patients admitted to tertiary care hospitals in Ethiopia: prospective observational study.
Beri B; Fanta K; Bekele F; Bedada W
BMC Cardiovasc Disord; 2023 Jan; 23(1):4. PubMed ID: 36609240
[TBL] [Abstract][Full Text] [Related]
17. Effect of evidence-based cardiac drug therapy on mortality in patients with acute coronary syndrome: Findings from the Gulf COAST registry.
Al-Zakwani I; Zubaid M; Alsheikh-Ali AA; Almahmeed W; Rashed W
Cardiovasc Ther; 2018 Dec; 36(6):e12463. PubMed ID: 30079461
[TBL] [Abstract][Full Text] [Related]
18. In-hospital management and mortality in elderly patients with non-ST-segment elevation acute coronary syndromes treated in centers without on-site invasive facilities.
Dziewierz A; Siudak Z; Rakowski T; Zdzienicka J; Dykla D; Mielecki W; Dubiel JS; Dudek D
Cardiol J; 2008; 15(5):451-7. PubMed ID: 18810721
[TBL] [Abstract][Full Text] [Related]
19. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
Vermeer NS; Bajorek BV
J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
[TBL] [Abstract][Full Text] [Related]
20. Effect of Secondary Prevention Medication on the Prognosis in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease.
Abdu FA; Liu L; Mohammed AQ; Xu B; Yin G; Xu S; Xu Y; Che W
J Cardiovasc Pharmacol; 2020 Dec; 76(6):678-683. PubMed ID: 33284169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
